Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.68 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.56 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.56 |
| ▸ | FAP | Q12884 | 4/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29477123 | 1.00 | DPP4 (0.68) | DPP4ACEDPP8DPP9DPP7 | |
| SCHEMBL7114188 | 1.00 | DPP4 (0.68) | DPP4ACEDPP8DPP9DPP7 | |
| SCHEMBL30423009 | 0.96 | DPP4 (0.63) | DPP4ACEDPP8DPP9DPP7 | |
| SCHEMBL30069061 | 0.95 | DPP4 (0.63) | DPP4ACEDPP8DPP9DPP7 | |
| SCHEMBL8892192 | 0.90 | DPP4 (0.68) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL27369439 | 0.90 | DPP4 (0.68) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL8892200 | 0.90 | DPP4 (0.68) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL3726263 | 0.90 | ACE (0.70) | DPP4ACEDPP8DPP9DPP7 | |
| SCHEMBL7375090 | 0.90 | ACE (0.70) | DPP4ACEDPP8DPP9DPP7 | |
| SCHEMBL3726264 | 0.90 | ACE (0.70) | DPP4ACEDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120189494-A | Use of adiponectin and adiponectin receptor agonists for the treatment of amyotrophic lateral sclerosis | 河北医科大学第二医院 | 2025-06-24 | — | — | CN | claimed |
| EP-4504166-A1 | TOPICAL FORMULATION FOR USE IN THE TREATMENT OR PREVENTION OF ITCHY DRY SKIN | MC2 Therapeutics Limited (GB) | 2025-02-12 | — | — | EP | claimed |
| US-12186312-B2 | Sleep improving agent | Amino Up Co., Ltd. (JP) | 2025-01-07 | — | — | US | claimed |
| CN-119192324-A | Tyr-Pro-casein peptide with sleep improving activity, and preparation method and application thereof | 华南理工大学 | 2024-12-27 | — | — | CN | claimed |
| CN-118984702-A | Topical preparation for treating or preventing dry skin itch | MC2疗法有限公司 | 2024-11-19 | — | — | CN | claimed |
| CN-112218875-B | Method for synthesizing arginine-containing peptides | 帝斯曼知识产权资产管理有限公司 | 2024-10-11 | — | — | CN | claimed |
| US-20240315296-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ CHEILJEDANG CORPORATION (KR) | 2024-09-26 | — | — | US | claimed |
| CN-117343139-B | Sea cucumber oligomerization active peptide, cellulose carrier, carrier complex, preparation method and application for treating liver injury diseases | 大连深蓝肽科技研发有限公司 | 2024-08-20 | — | — | CN | claimed |
| EP-4364582-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ Cheiljedang Corporation (KR) | 2024-05-08 | — | — | EP | claimed |
| CN-117677302-A | Peptide compounds for flavor modulation | CJ第一制糖株式会社 | 2024-03-08 | — | — | CN | claimed |
| US-11753440-B2 | Methods for the synthesis of arginine-containing peptides | DSM IP ASSETS B.V. (NL) | 2023-09-12 | — | — | US | claimed |
| EP-4225293-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | MC2 Therapeutics Limited (GB) | 2023-08-16 | — | — | EP | claimed |
| CN-116322671-A | Treatment of dermatological disorders | MC2疗法有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-115925788-A | Anglerfish swim bladder antioxidant peptide for treating non-alcoholic fatty liver disease and preparation method and application thereof | 浙江海洋大学 | 2023-04-07 | — | — | CN | claimed |
| WO-2023277549-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | 씨제이제일제당 (주) | 2023-01-05 | — | — | WO | claimed |
| CN-115053935-A | Application of lactobacillus salivarius in breeding of litopenaeus vannamei larvae | 华南理工大学 | 2022-09-16 | — | — | CN | claimed |
| WO-2022181712-A1 | COMPOSITION CONTAINING DECOMPOSED PRODUCTS OF VEGETABLE PROTEIN AND METHOD FOR PRODUCING SAME | 株式会社Mizkan Holdings | 2022-09-01 | — | — | WO | claimed |
| WO-2022074228-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | MC2 THERAPEUTICS LTD (GB) | 2022-04-14 | — | — | WO | claimed |
| CN-113896761-A | Synthetic method of L-tyrosyl-L-proline | 湖北泓肽生物科技有限公司 | 2022-01-07 | — | — | CN | claimed |
| EP-0457314-A1 | Nutrient compositions containing peptides | CLINTEC NUTRITION COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12186312-B2 | Sleep improving agent | HSF1, HSPH1, HSPA2 | DPP4 4255/4885ACE 4551/4885DPP8 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.